Page 1 of 2

Juvenile idiopathic arthritis: treatment with Etanercept

Three studies have shown the anti-TNF ( Tumour Necrosis Factor ) therapy Etanercept ( Enbrel ) to be effective, with a good safety profile, in children under four years of age with juvenile idiopathic arthritis ( JIA ), and associated with improved Health-Related Quality of Life ( HRQoL ) in a subst...
Read Article

Rheumatoid arthritis: Golimumab shows promising results in patients who have poor response to other TNF-alpha inhibitors

Golimumab ( Simponi ), a new tumour necrosis factor-alpha ( TNF-alpha ) blocker reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-alpha inhibitor, and might be a good option for patients who have inadequate responses to one or two other TNF...
Read Article

Potential biomarkers for psychosis and cerebrovascular disease in patients with systemic lupus erythematosus

Systemic lupus erythematosus ( SLE ) can affect nearly any part of the body, including the joints, skin, kidneys, heart, nervous system, and brain. Along with joint pain, muscle pain, unexplained fever, extreme fatigue, and skin rashes, neurologic and psychiatric events often accompany this autoimmu...
Read Article

Golimumab improves psoriatic arthritis symptoms

Patients with active psoriatic arthritis receiving monthly subcutaneous injections of Golimumab ( CNTO 148 ) experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest Phase 3 biologic study ever completed in subject...
Read Article

Alcohol intake associated with decreased risk of developing rheumatoid arthritis

New data suggests that alcohol may protect against rheumatoid arthritis, with three units a week exhibiting protective effects and ten units a week being more protective still. An alcohol consumption of three units per week or more also reduced the risk by smoking or by a genetic predisposition to...
Read Article

Combination therapy, Adalimumab plus Methotrexate, for achieving remission of early rheumatoid arthritis

Two-year study of patients with early, aggressive disease demonstrates significantly superior results of anti-TNF plus DMARD therapy over either therapy alone. A chronic and potentially crippling inflammatory disorder, rheumatoid arthritis progressively wears away the cartilage and bone. Joint er...
Read Article

FDA has approved Rituxan for treatment of moderate-to-severe rheumatoid arthritis

The FDA ( U.S. Food and Drug Administration ) has approved the therapeutic antibody Rituxan ( Rituximab ) in combination with Methotrexate to reduce signs and symptoms in adult patients with moderately-to-severely active rheumatoid arthritis who have had an inadequate response to one or more tumor n...
Read Article

Rheumatoid arthritis: Etanercept and Methotrexate combination has demonstrated improvement in physical function and kept joint damage from progressing

Data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis demonstrated that more than three quarters of patients treated with Enbrel ( Etanercept ) plus Methotrexate combination therapy experienced no progression of joint damage at three years. These new results ...
Read Article

Valproic acid, a common anti-seizure drug, could be effective for lupus

A animal research at Wake Forest University School of Medicine, found that a common anti-seizure drug may be effective against certain conditions associated with lupus. The drug, Valproic acid ( Depakote ), prevents skin disease and reduces the severity of kidney disease in a mouse model of lupu...
Read Article

dnaJP1 appears effective for rheumatoid arthritis

Researchers at the University of California, San Diego ( UCSD ) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis ( RA ). The new drug, dnaJP1, is a peptide derived from a naturally occurring protein, dnaJ...
Read Article